|
Join us virtually at JPM26 No images? Click here Can biopharma win the AI talent war?JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT Biopharma has an AI problem, and it's not about the technology. CHOOSE YOUR PASSAll in-person passes include access to the Endpoints Hub. Join us in-person on Monday & TuesdayJoin us in-person on Monday or TuesdayJoin us virtually (free)FEATURED SESSIONRobert Nelsen isn't known for holding back. The ARCH Venture Partners co-founder has been one of biotech's most vocal and successful investors, and he's sitting down with Endpoints to share an unfiltered take on the biggest disruptions facing the industry — from AI's real impact to the China question, and what both mean for the year ahead. View the full agenda here.
Robert Nelsen Charting biotech's course for 2026Catalent CEO Alessandro Maselli and John Carroll return for their annual predictions session, charting what's ahead for biotech in 2026. Last year, Carroll took heat for his bullish M&A forecast — until the second half proved him right with a string of blockbuster deals. This year, they're tackling everything from manufacturing pressures to funding dynamics and what the dealmaking momentum really means for the months ahead. NEW: In-person passes include access to our invite-only networking reception, featuring a live taping of Post-Hoc Live and special guest Noubar Afeyan, Founder and CEO of Flagship Pioneering. These conversations will set your agenda for navigating what's in store for next year. Join us. Virtual passes are available at no charge
|